Atherosclerosis
Volume 205, Issue 1 , Pages 319-324 , July 2009

C-reactive protein predicts functional status and correlates with left ventricular ejection fraction in patients with chronic stable angina

  • Ramón Arroyo-Espliguero

      Affiliations

    • Division of Cardiology, Hospital General Universitario, Guadalajara, Spain
    • These authors contributed equally to the study.
    • ,
  • Pablo Avanzas

      Affiliations

    • Division of Cardiology, Hospital Universitario Central de Asturias, Oviedo, Spain
    • These authors contributed equally to the study.
    • ,
  • Juan Quiles

      Affiliations

    • Division of Cardiology, Hospital San juan, Alicante, Spain
    • ,
  • Juan Carlos Kaski

      Affiliations

    • Division of Cardiac and Vascular Sciences, St. George's, University of London, Cranmer Terrace, London SW17 0RE, United Kingdom
    • Corresponding Author InformationCorresponding author. Tel.: +44 208 725 5901; fax: +44 208 725 3328.

Received 13 March 2008 ,Revised 3 December 2008 ,Accepted 8 December 2008.

References 

  1. Mann DL. Recent insights into the role of tumor necrosis factor in the failing heart. Heart Fail Rev. 2001;6:71–80
  2. Wollert KC, Drexler H. The role of interleukin-6 in the failing heart. Heart Fail Rev. 2001;6:95–103
  3. Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201–1206
  4. Bozkurt B, Kribbs S, Clubb FJ, et al. Pathophysiology relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97:1382–1391
  5. Murray DR, Freeman GL. Tumor necrosis factor-α induces a biphasic effect on myocardial contractility in conscious dogs. Circ Res. 1997;81:627–635
  6. Deswal A, Petersen NJ, Feldman AM, et al. Cytokines and cytokines receptors in advanced heart failure: an analysis of the cytokine database from the vesnarinone trial (VEST). Circulation. 2001;103:2055–2059
  7. Kelly RA, Smith TW. Cytokines and cardiac contractile function. Circulation. 1997;95:778–781
  8. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without a prior myocardial infarction: the Framingham Study. Circulation. 2003;107:1486–1491
  9. Pepys MB. CRP or not CRP? That is the question. Arterioscler Thromb Vasc Biol. 2005;25:1091–1094
  10. Ikeda U, Maeda Y, Yamamoto K, et al. C-reactive protein augments inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. Cardiovasc Res. 2002;56:86–92
  11. Sullivan DR, Marwick TH, Freedman SB. A new method of scoring coronary angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors. Am Heart J. 1990;119(6):1262–1267
  12. Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes: involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest. 1996;98:2854–2865
  13. Alonso-Martínez JL, Llorente-Diez B, Echegaray-Agara M, et al. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail. 2002;4:331–336
  14. Jones SA, Novick D, Horiuchi S, et al. C-reactive protein: a physiological activator of interleukin-6 receptor shedding. J Exp Med. 1999;189:599–604
  15. Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002;105:1890–1896
  16. Fichtlscherer S, Rosenberger G, Walter DH, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation. 2000;102:1000–1006
  17. Hambrecht R, Fiehn E, Weigl C, et al. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation. 1998;2709–2715
  18. Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med. 2000;343:1139–1147
  19. Arroyo-Espliguero R, Avanzas P, Cosín-Sales J, et al. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J. 2004;25:401–408
  20. Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure. Prognostic value and the effect of valsartan. Circulation. 2005;112:1428–1434
  21. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002;105:1760–1763
  22. Hartmann F, Packer M, Coats AJ, et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation. 2004;110:1780–1786
  23. Campbell DJ, Woodward M, Chalmers JP, et al. Prediction of heart failure by amino terminal-pro-B-type natriuretic peptide and C-reactive protein in subjects with cerebrovascular disease. Hypertension. 2005;45:69–74
  24. Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110:2168–2174
  25. Parissis JT, Adamopoulos S, Farmakis D, et al. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure. Heart. 2006;92:1768–1772
  26. Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial?. J Am Coll Cardiol. 2002;39:1567–1573
  27. Go AS, Lee WY, Yang J, et al. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA. 2006;296:2105–2111
  28. Bennett JA, Riegel B, Bittner V, et al. Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart Lung. 2002;31:262–270

PII: S0021-9150(08)00890-3

doi: 10.1016/j.atherosclerosis.2008.12.018

Atherosclerosis
Volume 205, Issue 1 , Pages 319-324 , July 2009

Article Tools

* Image Usage & Resolution